Skip to main content

Table 1 Baseline and in-hospital medication characteristics of the study sample by level of kidney function

From: Relationship between coronary artery disease and C-reactive protein levels in NSTEMI patients with renal dysfunction: a retrospective study

Variables Group A: Group B: Group C: P-value Post-hoc
GFR ≥60 GFR 59-30 GFR <30 Significant
  (n = 182) (n = 103) (n = 35)   Comparisons*
Age, mean (SD) (years) 68.7 (12.5) 81.2 (8.8) 79.5 (11.0) <.0001 A < B,C
Female, n (%) 49 (26.9) 46 (44.7) 23 (65.7) <.0001 A < B < C
History of lipid disorder, n (%) 106 (58.2) 59 (57.3) 15 (42.9) 0.236 -
History of diabetes, n (%) 45 (24.9) 37 (35.9) 18 (51.4) 0.004 A < B,C
History of hypertension, n (%) 130 (71.8) 87 (84.5) 29 (82.9) 0.035 A < B
History of PAD, n (%) 11 (6.1) 14 (13.6) 7 (20.0) 0.015 A < B,C
Prior myocardial infarction, n (%) 68 (37.6) 49 (48.0) 24 (70.6) 0.001 A,B < C
Prior stroke or TIA, n (%) 16 (8.8) 17 (16.5) 7 (20.0) 0.061 -
Left ventricular dysfunction (EF ≤ 40), n (%) 26 (14.3) 27 (26.2) 11 (31.4) 0.011 A < B,C
History of heart failure, n (%) 24 (13.2) 38 (36.9) 14 (40.0) <.0001 A < B,C
Renal function characteristics      
GFR at admission, mean (SD) (mL/min/1.73 m2 ) 81.1 (13.6) 45.5 (8.8) 18.1 (7.7) <.0001 A > B > C
GFR at peak, mean (SD) (mL/min/1.73 m2 ) 73.7 (16.4) 41.8 (10.1) 16.0 (9.3) <.0001 A > B > C
GFR at discharge, mean (SD) (mL/min/1.73 m2 ) 80.9 (15.8) 51.4 (15.4) 22.9 (16.9) <.0001 A > B > C
In-hospital medications, n (%)      
Aspirin 180 (98.9) 99 (96.1) 27 (77.1) <.0001 A,B > C
Clopidogrel 170 (93.4) 97 (94.2) 31 (88.6) 0.513 -
LMWH 179 (98.4) 95 (92.2) 33 (94.3) 0.037 A > B
Beta-blockers 177 (97.3) 93 (90.3) 32 (91.4) 0.036 A > B
ACE inhibitors 163 (91.1) 91 (88.3) 22 (62.9) <.0001 A,B > C
Statins 152 (84.4) 79 (77.5) 19 (54.3) <.0001 A,B > C
Immediate evidence-based treatment, n (%) 162 (89.0) 79 (76.7) 22 (62.9) <.0001 A > B,C
  1. *Bonferroni-corrected p value was used for Post-hoc analysis.
  2. Abbreviations: GFR glomerular filtration rate, SD standard deviation, PAD peripheral arterial disease, TIA transient ischemic attack, EF ejection fraction; LMWH low-molecular-weight-heparin, ACE angiotensin-converting enzyme.